18 results about "Ischemic Heart Diseases" patented technology

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

The invention provides application of S100A4 in preparation of a medicine for promoting myocardial cell proliferation. It is found that S100A4 not only can significantly induce proliferation of newborn mouse primary myocardial cells and hiPSC-CMs in vitro, but also can significantly improve the cardiac function after myocardial infarction and relieve ventricular fibrosis through AAV9-mediated cardiac targeting overexpression in vivo, and no obvious systemic toxic or side effect or tumorigenic signs are observed. Therefore, the S100A4 protein and the means of overexpressing the S100A4 can be used for promoting myocardial cell proliferation, so that the S100A4 protein can be used for improving or treating heart injury diseases such as ischemic heart disease and the like.

This application relates to the field of gene transduction technology, specifically disclosing a method and application for modifying mesenchymal stem cells (MSCs) targeting myocardial injury. The method includes: S1, obtaining umbilical cord-derived MSCs; S2, performing surface biomimetic modification on the MSCs; S3, gene editing on the MSCs; and S4, co-incubating the engineered MSCs with enzyme-responsive liposomes loaded with nitric oxide donors. The liposomes are embedded in a gelatin coating on the cell membrane surface through hydrophobic interactions, forming a targeted therapeutic system. This method for modifying MSCs targeting myocardial injury can be used for regenerative therapy and repair of myocardial injury diseases such as myocardial infarction and ischemic heart disease. It comprehensively improves the survival and stress tolerance of cells after implantation and enhances the targeting precision to the damaged site, thereby achieving the advantages of efficient, precise, and highly adaptable myocardial repair.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

Disclosed herein is a method for detecting cardiomyopathy and heart failure in a subject, the method involving assaying a sample from the subject for decrease in gene or protein expression of a Obg Like ATPase 1 (OLA1) and / or the presence of a Y254C mutation in OLA1, thereby detecting cardiomyopathy and heart failure in the subject. Also disclosed is a method for treating cardiomyopathy, heart failure, myocardial infarction or heart attack, ischemic heart disease, coronary heart disease and hypertrophic cardiomyopathy in a subject, the method involving administering to the subject an expression vector comprising a nucleic acid sequence encoding wild-type Obg Like ATPase 1 (OLA1) operably linked to an expression control sequence.

Reganoxonin is used in the preparation of a drug for the detection of ischemic heart disease by echocardiography. Echocardiography is selected from one or more of stress echocardiography, myocardial angiography, transthoracic Doppler echocardiography, and two-dimensional speckle tracking echocardiography. Ischemic heart disease is selected from one or more of non-obstructive or obstructive ischemic heart disease. The diagnosis of the patient's disease by administering the drug has good accuracy, sensitivity, specificity, and safety.

The invention relates to the technical field of medicines, in particular to ROS-triggered hydrogen sulfide donor derivatives as well as a preparation method and application thereof. The synthesis method of the beta-carboline hydrogen sulfide donor derivative is simple, and the beta-carboline hydrogen sulfide donor with dual functions can be obtained by condensing 4-phenylboronic acid pinacol ester thiobenzyl alcohol and different 3-position isothiocyanate substituted beta-carboline derivatives. The compound can recognize excessive oxygen free radicals generated in the myocardial ischemia reperfusion process, release hydrogen sulfide with a vascular protection effect and beta-carboline derivatives with myocardial protection activity at the same time, protect damaged myocardium from two aspects at the same time, have small influence on normal cells, and can be used for preparing a medicine for treating myocardial ischemia. And a new choice is provided for research and development of ischemic heart disease treatment drugs.

Part of this invention provides novel small molecule PHD inhibitors having structures according to formula (I) and its derivatives: or pharmaceutically acceptable salts thereof. The compounds provided herein may be used to treat the following diseases: including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory diseases (e.g., respiratory infections, acute respiratory distress syndrome), liver diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease), inflammatory bowel disease (IBD), ischemic-reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

The invention relates to the technical field of nucleic acid drugs and gene therapy, in particular to a preparation method and application of endothelial cell specific modRNA. The system comprises a number 1 modRNA and a number 2 modRNA, the number 1 modRNA encodes a target protein, a 5 '-untranslated region of the number 1 modRNA comprises an L7Ae protein binding element k-turn, the number 2 modRNA encodes an L7Ae protein, a 3'-untranslated region of the number 2 modRNA comprises at least one miR126 recognition sequence, and the number 1 modRNA and the number 2 modRNA are used for being delivered into an endothelial cell; the system has no genome integration risk, the expression is regulated and controlled by miR126 in real time, and the system is suitable for vascular regeneration of targeted endothelial cells, precise gene therapy of ischemic heart disease and the like.

A neural processing unit includes a controller to receive a compiled machine code of an artificial neural network (ANN) model for predicting cardiovascular disease, the ANN model configured to receive sensing data of ECG, respiration, pulse rate, acceleration, and / or body temperature and to output a probability of disease onset for cerebral infarction, heart failure, and / or ischemic heart disease in a user; an input circuit configured to receive a plurality of input signals corresponding to the ANN model; a processing element (PE) array to perform a calculation of the ANN model; a special function unit (SFU) to perform a special function of calculating the ANN model; and an on-chip memory to store operation data of the ANN model, wherein the controller controls the PE array, the SFU, and the on-chip memory to process the ANN model according to data locality information of the ANN model included in the compiled machine code.

This invention belongs to the field of biomedical technology, specifically relating to a composition for treating ischemic heart disease and its application. This invention combines two or more of ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re, and notoginsenoside R1, which can significantly downregulate the levels of myocardial enzymes, aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) in myocardial coronary effusion, with an inhibitory effect significantly higher than that of a single saponin component and the positive control drug verapamil. Simultaneously, the composition exhibits better recovery capabilities for coronary flow (CF), left ventricular developmental pressure (LVDP), maximum rate of decrease in left ventricular pressure (-dp / dtmax), and heart rate (HR) in myocardial coronary effusion. Therefore, the composition can alleviate and treat myocardial ischemia-reperfusion injury through multiple targets and mechanisms, fundamentally inhibiting the development of ischemic heart disease.

The application discloses a kind of adipose tissue-derived mitochondrial-derived vesicles and its preparation method and application, belong to the field of biological medicine.The preparation method includes obtaining mouse adipose tissue, including at least one of interscapular brown adipose tissue, epididymal white adipose tissue, beige adipose tissue, in vitro cultured adipocyte;Mouse adipose tissue homogenate is removed by differential centrifugation Unbroken cell, nucleus, mitochondrial and organelle precipitate, the supernatant obtained is treated by trypsin and then ultracentrifuged, the precipitate is collected, washed, to obtain mitochondrial-derived vesicles, which are membrane-coated vesicles, with a particle size of 100-200 nm, enriched in mitochondrial membrane proteins and oxidative phosphorylation-related proteins, and proved by ischemic heart disease model that it can improve heart function, reduce the degree of ventricular remodeling in mice with ischemic heart disease and reduce the fibrosis area, for the preparation of drugs for preventing or treating ischemic heart disease, and has important clinical application value.

Based on combination therapy, we propose a cell therapy that can significantly enhance the therapeutic effect of treatment for cerebrovascular disease, ischemic heart disease, or traumatic cerebrospinal nerve injury in subjects compared to conventional methods. [Solution] A cell preparation containing microglia and / or monocytes, which have the ability to promote angiogenesis and axon extension, is administered to the subject. By repeatedly implementing a bidirectional biofeedback loop between the nervous system and the musculoskeletal system, the effect of improving the motor function of the subject's brain, nervous system, and muscular system is enhanced.

Provided is a coronary blood flow measurement device capable of acquiring significant information for determination of ischemic heart disease caused by stenosis or the like in a coronary blood vessel on the basis of measurement of a blood flow (coronary blood flow) in a blood vessel (coronary blood vessel) of a heart. This coronary blood flow measurement device (10) includes: a CFR acquisition means (12) for acquiring a calculated value of coronary blood flow reserve (CFR); and a cCFR calculation means (14) for obtaining a blood pressure correction CFR (cCFR) by converting the calculated value of the coronary blood flow reserve (CFR) acquired by the CFR acquisition means into a value under a condition of an arbitrary specific value (ΔPs) of an arteriovenous pressure difference (ΔP(a-v)) by using a linear relationship between a maximum hyperemia coronary blood flow (Q(hyp.)) and the arteriovenous pressure difference (ΔP(a-v)).

The present invention addresses the problem of providing a new ischemic disease treatment strategy targeting pericytes. As a solution, the present invention provides an inflammation suppressant or a tissue protective agent for ischemic injury, each including an inhibitor which blocks ATP-sensitive potassium (KATP) channels present in a pericyte. In particular, the KATP channel is composed of pore-forming KIR6.1 and regulatory SUR2 subunits, and it is preferable for the inhibitor to act on the KIR6.1. The inflammation suppressant or the tissue protective agent for ischemic injury is preferably used in the treatment of ischemic diseases such as cerebral infarction or ischemic cardiac disease.

The application relates to the field of biological medicine, and provides application of OpiCa1 mutant peptide DE-4A in antagonizing heart failure after myocardial infarction. Experiments prove that the polypeptide DE-4A can remodel myocardial calcium homeostasis by restoring RyR2 protein stability and blocking excessive activation of the CaMKII signal pathway. This mechanism effectively reduces myocardial injury and fibrosis, significantly improves ventricular remodeling and heart dysfunction after myocardial infarction, and provides new experimental evidence for the treatment of ischemic cardiomyopathy. DE-4A has the effects of improving myocardial contractile function, regulating Ca 2+ homeostasis, which may be a key link in the pharmacodynamic mechanism, and provides new experimental evidence for the treatment of ischemic heart disease.

Provided in the present application are a phenylacrylamide compound, and a preparation method therefor and the use thereof. The phenylacrylamide compound has a structure represented by formula I. The phenylacrylamide compound provided in the present application can exhibit good binding to a plurality of target proteins, particularly exhibiting a good inhibitory activity against ACAT1 and 3-KAT targets, and has good bioavailability. The compound can be used in the preparation of a drug for preventing or treating tumors, cancer pain, radiotherapy- and chemotherapy-induced injuries, autoimmune diseases, infections, drug-induced myocarditis, cytokine storms, ischemic heart disease, inflammatory diseases and neurodegenerative diseases, or for anti-aging.